

# Javier Briones Mejjide

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8497898/javier-briones-mejjide-publications-by-citations.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

144  
papers

4,025  
citations

34  
h-index

61  
g-index

149  
ext. papers

4,647  
ext. citations

4.1  
avg, IF

4.47  
L-index

#	Paper	IF	Citations
144	Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. <i>Cell</i> , <b>2010</b> , 142, 699-713	56.2	672
143	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , <b>2019</b> , 393, 229-240	40	283
142	MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. <i>Haematologica</i> , <b>2013</b> , 98, 1554-62	6.6	165
141	Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. <i>Journal of Clinical Oncology</i> , <b>2009</b> , 27, 1462-9	2.2	163
140	Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. <i>Blood</i> , <b>2011</b> , 118, 1350-8	2.2	152
139	Rapid Engraftment Without Significant Graft-Versus-Host Disease After Allogeneic Transplantation of CD34+ Selected Cells From Peripheral Blood. <i>Blood</i> , <b>1997</b> , 89, 3967-3973	2.2	113
138	MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 4125-35	12.9	110
137	Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 155-61	12.9	103
136	CAR T-cells targeting FLT3 have potent activity against FLT3ITD AML and act synergistically with the FLT3-inhibitor crenolanib. <i>Leukemia</i> , <b>2018</b> , 32, 1168-1179	10.7	97
135	Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2002</b> , 29, 987-9	4.4	96
134	Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. <i>Haematologica</i> , <b>2007</b> , 92, 1489-94	6.6	94
133	Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. <i>Bone Marrow Transplantation</i> , <b>2004</b> , 34, 505-9	4.4	94
132	BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. <i>Experimental Hematology</i> , <b>2002</b> , 30, 135-41	3.1	92
131	Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. <i>Blood</i> , <b>2008</b> , 111, 5509-14	2.2	80
130	High-Titer Retroviral Vectors Containing the Enhanced Green Fluorescent Protein Gene for Efficient Expression in Hematopoietic Cells. <i>Blood</i> , <b>1997</b> , 90, 3316-3321	2.2	66
129	Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies. <i>European Journal of Haematology</i> , <b>2005</b> , 74, 144-51	3.8	65
128	Early and late neurological complications after reduced-intensity conditioning allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 1439-46	4.7	63

127	NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma. <i>Experimental Hematology</i> , <b>2008</b> , 36, 69-77	3.1	58
126	Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. <i>Blood</i> , <b>2000</b> , 95, 3085-3093	2.2	57
125	Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 413-20	4.7	53
124	Early clinical impact of iron overload in stem cell transplantation. A prospective study. <i>Annals of Hematology</i> , <b>2007</b> , 86, 443-7	3	52
123	Multicenter phase II study of plitidepsin in patients with relapsed/refractory non-Hodgkin's lymphoma. <i>Haematologica</i> , <b>2013</b> , 98, 357-63	6.6	43
122	Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. <i>Journal of the National Cancer Institute</i> , <b>2003</b> , 95, 548-55	9.7	42
121	Impact of Epstein Barr virus-related complications after high-risk allo-SCT in the era of pre-emptive rituximab. <i>Bone Marrow Transplantation</i> , <b>2015</b> , 50, 579-84	4.4	41
120	Lower respiratory tract respiratory virus infections increase the risk of invasive aspergillosis after a reduced-intensity allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , <b>2009</b> , 44, 749-56	4.4	41
119	T-cell costimulatory molecules in acute-graft-versus host disease: therapeutic implications. <i>Bone Marrow Research</i> , <b>2011</b> , 2011, 976793		40
118	In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma. <i>Cancer Research</i> , <b>2002</b> , 62, 3195-9	10.1	39
117	Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP). <i>British Journal of Haematology</i> , <b>2010</b> , 148, 235-44	4.5	38
116	Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. <i>British Journal of Haematology</i> , <b>2009</b> , 145, 801-5	4.5	38
115	Study of kidney function impairment after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation. A single-center experience. <i>Biology of Blood and Marrow Transplantation</i> , <b>2009</b> , 15, 21-9	4.7	37
114	Prognostic indexes in follicular lymphoma: a comparison of different prognostic systems. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1508-13	10.3	36
113	Clinical utility of bone marrow flow cytometry in B-cell non-Hodgkin lymphomas (B-NHL). <i>Histopathology</i> , <b>2004</b> , 45, 268-74	7.3	35
112	Patterns of infection and infection-related mortality in patients with steroid-refractory acute graft versus host disease. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 107-113	4.4	34
111	Patients with biochemical iron overload: causes and characteristics of a cohort of 150 cases. <i>Annals of Hematology</i> , <b>2003</b> , 82, 127-130	3	34
110	LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 621-30	4.5	30

109	Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2006</b> , 12, 1135-41	4.7	29
108	Effects of G-CSF administration and peripheral blood progenitor cell collection in 20 healthy donors. <i>Annals of Hematology</i> , <b>1996</b> , 72, 269-72	3	29
107	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , <b>2014</b> , 99, 505-10	6.6	26
106	Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression. <i>Experimental Hematology</i> , <b>2011</b> , 39, 1064-71	3.1	26
105	PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. <i>Advances in Clinical and Experimental Medicine</i> , <b>2015</b> , 24, 325-30	1.8	26
104	Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , <b>2006</b> , 85, 597-603	3	24
103	Reduced-intensity conditioning allogeneic blood stem cell transplantation with fludarabine and oral busulfan with or without pharmacokinetically targeted busulfan dosing in patients with myeloid leukemia ineligible for conventional conditioning. <i>Biology of Blood and Marrow Transplantation</i> , <b>2005</b> , 11, 437-47	4.7	24
102	High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. <i>Haematologica</i> , <b>2008</b> , 93, 207-14	6.6	23
101	Role of the STAT1 pathway in apoptosis induced by fludarabine and JAK kinase inhibitors in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 435-42	1.9	23
100	Activation of the NF-kappaB signalling pathway in diffuse large B-cell lymphoma: clinical implications. <i>Histopathology</i> , <b>2008</b> , 53, 441-9	7.3	21
99	Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease. <i>Clinical and Experimental Immunology</i> , <b>2006</b> , 145, 36-43	6.2	21
98	CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: high purging efficiency but increased risk of severe infections. <i>Experimental Hematology</i> , <b>2002</b> , 30, 824-30	3.1	21
97	Strategies to reduce transplant-related mortality after allogeneic stem cell transplantation in elderly patients: Comparison of reduced-intensity conditioning and unmanipulated peripheral blood stem cells vs a myeloablative regimen and CD34+ cell selection. <i>Experimental Hematology</i> , <b>2003</b> , 31, 1039-43	3.1	21
96	Bcl-10 protein highly correlates with the expression of phosphorylated p65 NF-kappaB in peripheral T-cell lymphomas and is associated with clinical outcome. <i>Histopathology</i> , <b>2009</b> , 54, 478-85	7.3	19
95	Low transplant related mortality in older patients with hematologic malignancies undergoing autologous stem cell transplantation. <i>Haematologica</i> , <b>2003</b> , 88, 300-5	6.6	19
94	Does reduced-intensity allogeneic transplantation confer a survival advantage to patients with poor prognosis chronic lymphocytic leukaemia? A case-control retrospective analysis. <i>Annals of Oncology</i> , <b>2009</b> , 20, 2007-12	10.3	18
93	Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response. <i>Gene Therapy</i> , <b>2010</b> , 17, 469-77	4	17
92	Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: longitudinal analysis from 1994 to 2008 at a single institution. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 690-701	4.4	17

91	A Randomized Phase II Study Comparing Consolidation With a Single Dose Of 90y Ibritumomab Tiuxetan (Zevalin <sup>®</sup> ) (Z) Vs. Maintenance With Rituximab (R) For Two Years In Patients With Newly Diagnosed Follicular Lymphoma (FL) Responding To R-CHOP. Preliminary Results At 36 Months From Randomization. <i>Blood</i> , <b>2013</b> , 122, 369-369	2.2	17
90	Study of hematopoietic chimerism following allogeneic peripheral blood stem cell transplantation using PCR amplification of short tandem repeats. <i>Annals of Hematology</i> , <b>1996</b> , 72, 265-8	3	16
89	Degree of mucositis and duration of neutropenia are the major risk factors for early post-transplant febrile neutropenia and severe bacterial infections after reduced-intensity conditioning. <i>European Journal of Haematology</i> , <b>2012</b> , 88, 46-51	3.8	15
88	Pulmonary function testing prior to reduced intensity conditioning allogeneic stem cell transplantation in an unselected patient cohort predicts posttransplantation pulmonary complications and outcome. <i>American Journal of Hematology</i> , <b>2012</b> , 87, 9-14	7.1	15
87	Emerging therapies for patients with advanced chronic lymphocytic leukaemia. <i>Blood Reviews</i> , <b>2009</b> , 23, 217-24	11.1	14
86	Dendritic cells combined with tumor cells and $\beta$ -galactosylceramide induce a potent, therapeutic and NK-cell dependent antitumor immunity in B cell lymphoma. <i>Journal of Translational Medicine</i> , <b>2017</b> , 15, 115	8.5	13
85	Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy. <i>British Journal of Haematology</i> , <b>2016</b> , 174, 859-67	4.5	12
84	Epidemiology of lymphoid malignancies: last decade update. <i>SpringerPlus</i> , <b>2013</b> , 2, 70		12
83	Hypercalcemia in a patient with chronic lymphocytic leukemia evolving into Richter's syndrome. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 21, 521-3	1.9	12
82	Efficient transduction of human hematopoietic repopulating cells generating stable engraftment of transgene-expressing cells in NOD/SCID mice. <i>Blood</i> , <b>2000</b> , 95, 3085-3093	2.2	12
81	Do Patients and Physicians Agree When They Assess Quality of Life?. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1005-1010	4.7	10
80	Updated experience with inolimomab as treatment for corticosteroid-refractory acute graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2013</b> , 19, 435-9	4.7	10
79	Impact of cyclosporine levels on the development of acute graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. <i>Mediators of Inflammation</i> , <b>2014</b> , 2014, 620682	4.3	10
78	Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial. <i>Blood</i> , <b>2019</b> , 134, 126-126	2.2	10
77	Emerging therapies for B-cell non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , <b>2009</b> , 9, 1305-16	3.6	9
76	Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. <i>Cancer Medicine</i> , <b>2021</b> , 10, 3214-3223	4.8	9
75	Incorporating posttransplant cyclophosphamide-based prophylaxis as standard-of-care outside the haploidentical setting: challenges and review of the literature. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1041-1049	4.4	8
74	Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial. <i>Haematologica</i> , <b>2014</b> , 99, e126	6.6	7

73	Focal adhesion protein expression in human diffuse large B-cell lymphoma. <i>Histopathology</i> , <b>2014</b> , 65, 119-31	7.3	7
72	The use of tetradecanoylphorbol acetate-stimulated peripheral blood cells enhances the prognostic value of interphase fluorescence in situ hybridization in patients with chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2010</b> , 49, 327-32	5	7
71	Safety and efficacy of low-dose amphotericin B lipid complex for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies. <i>Methods and Findings in Experimental and Clinical Pharmacology</i> , <b>2001</b> , 23, 505-10		7
70	International and Italian prognostic indices in follicular lymphoma. <i>Haematologica</i> , <b>2003</b> , 88, 700-4	6.6	7
69	Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial. <i>Annals of Hematology</i> , <b>2017</b> , 96, 639-646	3	6
68	Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine + Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 578-585	4.7	6
67	When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (thiotepa-busulfan-fludarabine). <i>Annals of Hematology</i> , <b>2020</b> , 99, 157-165	3	6
66	New therapies in non-Hodgkin lymphoma. <i>Expert Review of Anticancer Therapy</i> , <b>2015</b> , 15, 349-59	3.5	5
65	Targeted therapy of BCL6-dependent diffuse large B-cell lymphomas by heat-shock protein 90 inhibition. <i>Expert Review of Hematology</i> , <b>2010</b> , 3, 157-9	2.8	5
64	Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 797-807	4.5	5
63	Alemtuzumab treatment for Sjögren syndrome: A single-center experience. <i>Journal of Dermatological Treatment</i> , <b>2016</b> , 27, 179-81	2.8	4
62	Silent T-cell receptor cutaneous T-cell lymphoma associated to a clonal plasma cell proliferation. <i>Hematology Reports</i> , <b>2019</b> , 11, 7841	0.9	4
61	Long-Term Follow-Up of a Phase II Trial of Six Cycles of Dose-Dense R-CHOP-14 for First-Line Treatment of Diffuse Large B-Cell Lymphoma in Young and Elderly Patients. <i>Acta Haematologica</i> , <b>2016</b> , 136, 76-84	2.7	4
60	Heat-shock proteins: a c-Myc lymphoma target?. <i>Blood</i> , <b>2015</b> , 125, 1685-6	2.2	4
59	Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen. <i>Cytotherapy</i> , <b>2009</b> , 11, 356-61	4.8	4
58	Demonstration of donor origin of CD34+ HLA-DR- bone marrow cells after allogeneic peripheral blood transplantation with a long follow-up. <i>Bone Marrow Transplantation</i> , <b>1998</b> , 21, 189-94	4.4	4
57	Mobilization kinetics of peripheral blood progenitor cells after IAPVP-16 salvage chemotherapy plus G-CSF in lymphoproliferative disorders. <i>Bone Marrow Transplantation</i> , <b>2000</b> , 26, 127-32	4.4	4
56	Real-World Evidence of Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. <i>Blood</i> , <b>2020</b> , 136, 19-21	2.2	4



55	Polatuzumab vedotin (Pola) + obinutuzumab (G) and lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Interim analysis of a phase Ib/II trial.. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 7505-7505	2.2	4
54	Using the Lymph2Cx assay for assessing cell-of-origin subtypes of HIV-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 1087-1091	1.9	4
53	Assessment of Confirmed Clinical Hypersensitivity to Rituximab in Patients Affected with B-Cell Neoplasia. <i>Advances in Hematology</i> , <b>2020</b> , 2020, 4231561	1.5	3
52	Total body-surface area as a new prognostic variable in mycosis fungoides and Sřary syndrome. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 1060-6	1.9	3
51	Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas. <i>International Journal of Hematology</i> , <b>2019</b> , 110, 406-410	2.3	3
50	Therapeutic vaccines for non-Hodgkin B-cell lymphoma. <i>Clinical and Translational Oncology</i> , <b>2008</b> , 10, 543-51	3.6	3
49	Long Term Follow-up of a Phase 2 Study Examining Intratumoral G100 Alone and in Combination with Pembrolizumab in Patients with Follicular Lymphoma. <i>Blood</i> , <b>2018</b> , 132, 2892-2892	2.2	3
48	The novel agonistic iNKT-cell antibody NKT14m induces a therapeutic antitumor response against B-cell lymphoma. <i>Oncolmmunology</i> , <b>2019</b> , 8, e1546543	7.2	3
47	Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients. <i>Annals of Hematology</i> , <b>2021</b> , 100, 1023-1029	3	3
46	Phase 1b study of the BET protein inhibitor RO6870810 with venetoclax and rituximab in patients with diffuse large B-cell lymphoma. <i>Blood Advances</i> , <b>2021</b> , 5, 4762-4770	7.8	3
45	Allogeneic hematopoietic stem cell transplantation for non-Hodgkin’s lymphomas: a retrospective analysis of 77 cases. <i>Annals of Hematology</i> , <b>2017</b> , 96, 787-796	3	2
44	Allogenic transplants with peripheral blood progenitor cells: a report of six cases. <i>Leukemia and Lymphoma</i> , <b>1996</b> , 20, 471-4	1.9	2
43	Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial.. <i>Blood</i> , <b>2008</b> , 112, 1566-1566	2.2	2
42	Validation of Comorbidity Indexes in Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation. the Hematopoietic Cell Transplantation Comorbidity Index Is the Best Predictor of NRM and Survival.. <i>Blood</i> , <b>2008</b> , 112, 3277-3277	2.2	2
41	A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin’s Lymphoma: Interim Safety Data From The Mabcute Study. <i>Blood</i> , <b>2013</b> , 122, 3052-3052	2.2	2
40	Myeloablative Versus Reduced Intensity Allogeneic Stem Cell Transplantation in Relapsed Hodgkin’s Lymphoma in Recent Years. a Retrospective Analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Blood</i> , <b>2014</b> , 124, 2562-2562	2.2	2
39	Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 7537-7537	2.2	2
38	Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study. <i>Lancet Haematology,the</i> , <b>2021</b> , 8, e891-e901	14.6	2

37	Fludarabine-induced apoptosis in CD19+/CD5+B-CLL cells is a direct and nurse-like-cell independent effect. <i>Leukemia and Lymphoma</i> , <b>2004</b> , 45, 2307-14	1.9	1
36	Evolution of Outcome over Time for Relapsed Hodgkin Lymphoma after Autologous Stem Cell Transplant: Improved Survival for Early Relapse in Recent Years. <i>Blood</i> , <b>2020</b> , 136, 9-10	2.2	1
35	Paraffin-Based 6-Gene Model Predicts Outcome of Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP.. <i>Blood</i> , <b>2007</b> , 110, 49-49	2.2	1
34	Autologous Stem Cell Transplantation with Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Plus BEAM Conditioning in Patients with Refractory Non-Hodgkin Diffuse Large B-Cell Lymphoma: Results of a Prospective, Multicenter, Phase II Clinical Trial. <i>Blood</i> , <b>2012</b> , 120, 1978-1978	2.2	1
33	A First-in-Human Study of YTB323, a Novel, Autologous CD19-Directed CAR-T Cell Therapy Manufactured Using the Novel T-Charge™ platform, for the Treatment of Patients (Pts) with Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2021</b> , 138, 740-740	2.2	1
32	Efficacy and Safety of Ruxolitinib in Steroid-Refractory/Dependent Chronic Graft-versus-Host Disease: Real-World Data and Challenges. <i>Transplantation and Cellular Therapy</i> , <b>2021</b> , 28, 43.e1-43.e1		1
31	Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions.. <i>Blood</i> , <b>2009</b> , 114, 622-622	2.2	1
30	Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma. <i>Clinical and Translational Immunology</i> , <b>2021</b> , 10, e1268	6.8	1
29	Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , <b>2018</b> , 18, 737-742	2	1
28	A randomized phase II study comparing consolidation with a single dose of Y ibritumomab tiuxetan maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-8	1.9	1
27	Axicabtagene Ciloleucl Compared to Tisagenlecleucl for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain. <i>Blood</i> , <b>2021</b> , 138, 1742-1742	2.2	0
26	Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2021</b> , 196, 589	4.5	0
25	Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin lymphoma and in Hodgkin lymphoma survivors. <i>European Journal of Haematology</i> , <b>2021</b> , 106, 697-707	3.8	0
24	Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 1-13	1.9	0
23	Low Rate of Invasive Fungal Infections During Induction and Consolidation Chemotherapy for Adults with De Novo Acute Myeloid Leukemia Without Anti-mold Prophylaxis: Single-Center 2002-2018 Empirical/Pre-emptive Approach. <i>Mycopathologia</i> , <b>2020</b> , 185, 639-652	2.9	
22	CAR-T Cells with High CAR Expression Intensity Have Improved In Vitro and In Vivo Anti-Lymphoma Effect without Functional Exhaustion. <i>Blood</i> , <b>2020</b> , 136, 34-34	2.2	
21	Brentuximab Vedotin Plus ESHAP (BRESHAP) Versus ESHAP As Salvage Strategy for Patients with Primary Refractory or Relapsed Classical Hodgkin's Lymphoma. Preliminary Results from the Breselibet Prospective Clinical Trial. <i>Blood</i> , <b>2021</b> , 138, 2459-2459	2.2	
20	Rituximab-Mediated Antibody-Dependent Cellular Cytotoxicity Is Enhanced by Interleukin-15 or CpG Oligodeoxynucleotides.. <i>Blood</i> , <b>2005</b> , 106, 2440-2440	2.2	



- 19 Long Remission Are Possible after Non Myeloablative Transplant in Patients with Follicular Non-Hodgkin's Lymphoma (NHL): Results of Two Prospectives Multicenter Trials.. *Blood*, **2006**, 108, 3024-3024
- 18 Efficacy of Dose-Dense R-CHOP-14 Chemoimmunotherapy Plus Pegfilgrastim for First-Line Treatment of Diffuse Large B-Cell Lymphoma (DLBCL) in Low Risk Patients: An Interim Analysis of an Open-Label Clinical Trial in Spain. On Behalf of GEL/TAMO (Spanish Group of Lymphoma).. *Blood*, **2007**, 110, 3443-3443 2.2
- 17 Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Using Oral Fludarabine as Part of the Conditioning Regimen.. *Blood*, **2007**, 110, 4925-4925 2.2
- 16 Comparison of Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate in Reduced Intensity Conditioning HLA Sibling Allogeneic Stem Cell Transplantation. A Case-Match Single-Center Experience.. *Blood*, **2007**, 110, 4994-4994 2.2
- 15 Management experience of advanced-stage mycosis fungoides/Szary syndrome: a retrospective study from Spanish haematology referral units. *European Journal of Dermatology*, **2020**, 30, 397-403 0.8
- 14 Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma: A Retrospective Study of the Geltamo Group (1994-2011). *Blood*, **2014**, 124, 3980-3980 2.2
- 13 Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. *Blood*, **2016**, 128, 152-152 2.2
- 12 Treatment of Chronic Myeloid Leukemia with Imatinib. A Single Centre Experience. *Blood*, **2008**, 112, 4289-4289 2.2
- 11 Therapeutic Antimyeloma Effect of Dendritic-Tumor Cells Hybrids Transduced with Adenovirus Encoding CD40L.. *Blood*, **2008**, 112, 1709-1709 2.2
- 10 Relapse after Autologous Stem Cell Transplant (ASCT) for Diffuse Large B Cell Lymphoma: Clinical Outcome and Prognostic Factors Affecting Long-Term Outcome. *Blood*, **2008**, 112, 2593-2593 2.2
- 9 Targeting the Poor Mobilizing Population of Patients for An Autologous Transplantation Procedure: A Single Centre Experience. *Blood*, **2008**, 112, 4136-4136 2.2
- 8 T-Cell Receptor Signaling Proteins, BCL10 and Phosphorylated-P65 NFkB, Are Expressed in Peripheral T-Cell Lymphomas and Associated with Clinical Outcome. *Blood*, **2008**, 112, 2820-2820 2.2
- 7 The Use of Tetradenoylphorbol Acetate Stimulated Peripheral Blood Cells for Interphase Fluorescence In-Situ Hybridization Analysis May Enhance Its Prognostic Value for Patients with Chronic Lymphocytic Leukemia. *Blood*, **2008**, 112, 4152-4152 2.2
- 6 Therapeutic Compliance and Efficacy of Dose-Dense R-CHOP-14 Immunochemotherapy Plus Pegfilgrastim for First-Line Treatment of Low Risk Diffuse Large B-Cell Lymphoma Patients: Preliminary Results of An Open-Label Clinical Trial in Spain. *Blood*, **2008**, 112, 4943-4943 2.2
- 5 MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma.. *Blood*, **2009**, 114, 624-624 2.2
- 4 Long-Term Follow-Up Of Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation For High Risk Follicular Lymphoma. *Blood*, **2013**, 122, 5519-5519 2.2
- 3 Efficacy and Safety Of Temsirolimus In Patients With Relapsed Or Refractory Mantle Cell Lymphoma: Results From The Spanish Experience. *Blood*, **2013**, 122, 5117-5117 2.2
- 2 Cancer Vaccines: Fundamentals and Strategies. *Advances in Delivery Science and Technology*, **2014**, 163-185

- 1 Marginal zone lymphoma under anti-TNF treatment in Crohn disease. *Gastroenterology Y Hepatología*, **2021**, 0.9